Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of PCV-free Liquid Rotarix in Infants
NCT03954743Phase 3Completed
- Sponsor
- GSK
- Start
- Jul 2019
- Primary completion
- Nov 2020
- Modality
- Live Attenuated Vaccines
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial of rotavirus vaccine, live, oral in rotavirus gastroenteritis (2 arms), sponsored by GSK. Primary endpoints: Number of Subjects With Any Solicited General Adverse Events (AEs) After the First Vaccination at 8 days, Number of Subjects With Any Solicited General Adverse Events (AEs) After the Second Vaccination at 8 days and 2 more. Started Jul 2019; status: completed.
02
Drugs
rotavirus vaccine, live, oral
03
Conditions
rotavirus gastroenteritis
Beyond the preview
Go deeper on NCT03954743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03954743.